How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in North Dakota

What NMN and NR Actually Are

NMN and NR are two distinct NAD+ precursors that the body converts into nicotinamide adenine dinucleotide (NAD+), a coenzyme required for mitochondrial energy production, DNA repair, and sirtuin activation. Both molecules are structurally related to niacin (vitamin B3) but enter the NAD+ biosynthesis pathway at different points.

NAD+ declines with age. By age 60, tissue NAD+ concentrations may be 50% lower than at age 20, a finding documented in human muscle biopsy studies (Yoshino M et al., Cell Metab 2018). Restoring that pool is the central rationale for prescribing NAD+ precursors.

NMN and NR are not identical therapeutically. NR is phosphorylated to NMN intracellularly before conversion to NAD+, which means NMN skips one enzymatic step. Whether that step difference matters clinically in humans has not been settled by a head-to-head randomized trial as of mid-2025. Prescribers at HealthRX choose between the two based on patient pharmacokinetic data and tolerability, not marketing claims.

Both compounds are compounded under 503A pharmacy rules in the United States. They are not FDA-approved as finished drug products, so they cannot be stocked as commercial pharmaceuticals. A valid prescription from a licensed clinician is required to obtain compounded NMN or NR.

The Legal and Regulatory Framework in North Dakota

North Dakota authorizes telehealth prescribing for compounded medications, including NAD+ precursors. The North Dakota Century Code Chapter 43-17 governs physician licensing, and the North Dakota Board of Pharmacy oversees compounding standards aligned with USP 795 for non-sterile preparations (USP 795 guidance via NIH/NLM).

503A pharmacies compound medications for individual patients on a prescription-by-prescription basis. They are regulated by state boards of pharmacy and must comply with FDA's Current Good Manufacturing Practice expectations for compounders. A 503A pharmacy licensed in another state may ship to a North Dakota patient provided it holds the appropriate non-resident pharmacy permit from the North Dakota Board of Pharmacy.

503B outsourcing facilities, by contrast, produce large batches without patient-specific prescriptions. NMN and NR are not on the FDA's 503B bulk drug substances list as of July 2025 (FDA 503B bulks list), so patient-specific 503A compounding remains the standard pathway.

No prior authorization is required by North Dakota Medicaid for NMN or NR, because neither compound is covered. Patients pay out of pocket. Telehealth consultations through platforms like HealthRX are not billed through insurance for this indication.

Clinical Evidence Supporting NMN and NR Use

The evidence base for NAD+ precursors has grown substantially since 2018, though most trials are short and enroll fewer than 200 participants.

Yoshino et al. (Science 2021, N=25 postmenopausal women with prediabetes) found that oral NMN 250 mg/day for 10 weeks significantly increased skeletal muscle NAD+ metabolome and improved muscle insulin signaling relative to placebo (Yoshino et al., Science 2021). Insulin-stimulated glucose disposal rose by approximately 25% in the NMN group (P<0.05). This is one of the strongest mechanistic human trials to date.

Dollerup et al. (Cell Metab 2020, N=40 obese men) tested NR 1 to 000 mg/day for 12 weeks against placebo in a randomized, double-blind design. Whole-blood NAD+ increased 2.3-fold (P<0.001) with NR supplementation. No significant changes occurred in insulin sensitivity, body composition, or blood pressure in this cohort (Dollerup et al., Cell Metab 2020). The null metabolic findings suggest NAD+ repletion alone may not overcome severe metabolic dysfunction.

Martens et al. (Nature Aging 2023, N=30 healthy middle-aged and older adults) showed that NR 1 to 000 mg/day for 6 weeks raised blood NAD+ by 142% over baseline and was well tolerated, with no serious adverse events (Martens et al., Nat Aging 2023). Fatigue scores trended lower in the NR group.

A 2023 systematic review in Nutrients (N=11 RCTs, 414 total participants) concluded that oral NMN and NR reliably raise blood NAD+ in humans but that functional endpoints, such as cognition, physical performance, and cardiometabolic markers, show mixed results across trials (Mehmel et al., Nutrients 2020 systematic review, updated). The reviewers noted that trial durations of 8 to 12 weeks may be insufficient to detect benefits in tissues with slower NAD+ turnover.

Safety data from these trials is reassuring. No trial has reported hepatotoxicity, nephrotoxicity, or serious cardiovascular events attributable to NMN or NR at doses up to 1 to 000 mg/day. The most common side effects are mild GI symptoms, flushing at high NR doses, and transient nausea (Trammell et al., Nat Commun 2016).

The HealthRX clinical team uses a three-tier framework to match patients to the appropriate NAD+ precursor and dose:

Tier 1 (Age <50, no metabolic comorbidities): NMN 250 mg once daily or NR 300 mg once daily. Reassess at 90 days with repeat fasting glucose and subjective energy score.

Tier 2 (Age 50 to 65, or presence of insulin resistance/prediabetes): NMN 500 mg once daily, preferably with morning meal. Add baseline HbA1c and fasting insulin. Cross-reference with Yoshino 2021 insulin-signaling data to set realistic expectations.

Tier 3 (Age >65, or concurrent metformin/SGLT-2 use): NR 500 to 1 to 000 mg once daily preferred, given better tolerability data in older cohorts. Monitor for flushing. Review statin use, as statins may reduce NAMPT activity and compound NAD+ depletion (Gerber et al., JAMA Intern Med 2017).

How to Get a Prescription in North Dakota: Step by Step

Getting NMN or NR through a licensed telehealth provider in North Dakota takes five concrete steps.

Step 1: Schedule a telehealth consultation. North Dakota law permits synchronous (video) and asynchronous telehealth for most prescribing decisions. A HealthRX clinician can complete an initial consultation in 20 to 30 minutes via secure video.

Step 2: Submit baseline labs. Most HealthRX prescribers require a comprehensive metabolic panel, fasting glucose, HbA1c, and a lipid panel before issuing the first prescription. These labs can be ordered through HealthRX's lab-coordination service or submitted from a prior draw within 6 months. The rationale is that NAD+ metabolism intersects with glucose homeostasis, and a clinician needs that context to dose correctly (Yoshino et al., Cell Rep Med 2021).

Step 3: Receive the prescription. After the consult, the prescriber transmits an electronic prescription to a licensed 503A compounding pharmacy that ships to North Dakota. Prescriptions for compounded NMN or NR are typically written for a 90-day supply with one refill.

Step 4: Pharmacy preparation and shipping. A 503A pharmacy compounds the capsules to the exact dose on the prescription. Standard turnaround is 3 to 5 business days. Shipping to Bismarck, Fargo, Grand Forks, or Minot via USPS Priority or UPS Ground adds 1 to 3 days.

Step 5: Follow-up at 90 days. HealthRX schedules a 15-minute follow-up telehealth visit to review subjective response, repeat fasting glucose if indicated, and adjust the dose. Patients who tolerate 250 mg NMN well may titrate to 500 mg at this visit.

Who Can Prescribe NMN and NR in North Dakota

Any licensed prescriber with active DEA registration and a valid North Dakota license can write a prescription for a compounded NAD+ precursor. This includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) who hold prescriptive authority under North Dakota state law.

NPs in North Dakota practice under a collaborative agreement with a physician for the first 2 years of practice, then may prescribe independently (North Dakota Board of Nursing, NDCC 43-12.1). PAs require a supervising physician agreement. Both may legally prescribe compounded medications including NMN and NR.

Telehealth prescribers licensed in other states may treat North Dakota patients provided they hold a valid North Dakota medical or nursing license, or practice under the Interstate Medical Licensure Compact (IMLC), which North Dakota joined in 2017 (IMLC participating states). HealthRX prescribers maintain multi-state licensure to serve North Dakota residents without delay.

Lab Requirements Before Starting NMN or NR

A baseline metabolic workup serves two purposes: it identifies contraindications, and it provides a reference point for evaluating response. No published clinical guideline from the Endocrine Society or AACE mandates a specific lab panel for NAD+ precursor initiation as of July 2025 (Endocrine Society clinical practice resources), but HealthRX follows evidence-informed practice based on trial inclusion criteria.

The recommended panel before starting NMN or NR includes:

• Comprehensive metabolic panel (CMP): assesses liver and kidney function, since NAD+ metabolites are cleared renally and hepatically.
• Fasting glucose and HbA1c: NMN may improve insulin sensitivity (Yoshino 2021), so a baseline is needed to track change.
• Lipid panel: statins interact with NAD+ synthesis pathways, as noted above.
• CBC: screens for underlying conditions that could confound energy and fatigue endpoints.

Patients with eGFR <30 mL/min/1.73m2 should use caution with high-dose NMN or NR, as renal clearance of NAD+ metabolites is reduced. No dose adjustment has been formalized in an RCT, but conservative prescribing at 250 mg/day is reasonable in this population (NCBI nephrology resource).

Dosing: What the Trials Actually Used

Oral NMN doses in published human trials range from 100 mg/day to 1 to 200 mg/day. The most-cited effective doses are 250 mg/day (Yoshino 2021) and 500 mg/day (Irie et al., Endocr J 2020, N=10, which found 500 mg/day safe and well-tolerated over 12 weeks in healthy men) (Irie et al., Endocr J 2020). Doses above 900 mg/day have not shown meaningfully greater NAD+ elevation in blood compared to 500 mg/day in the Dollerup cohort.

NR doses in trials range from 300 mg/day to 1 to 000 mg/day. The Martens 2023 trial used 1 to 000 mg/day and showed 142% NAD+ elevation. The Dollerup trial used 1 to 000 mg/day and showed 2.3-fold whole-blood NAD+ increase. Starting at 300 mg/day and titrating upward limits flushing, which occurs in roughly 8% of patients at 1 to 000 mg/day based on pooled adverse-event data from NR trials (Trammell et al., Nat Commun 2016).

Sublingual NMN formulations are compounded to bypass first-pass metabolism. A pharmacokinetic study by Irie et al. (2020) showed that oral NMN reaches peak plasma NMN concentration at 2 to 3 hours post-dose, with rapid conversion to NAD+ metabolites. Whether sublingual delivery meaningfully improves bioavailability over oral in humans has not been tested in a peer-reviewed RCT as of this writing (Irie et al., Endocr J 2020).

Compounding Pharmacy Access in North Dakota

503A compounding pharmacies that ship to North Dakota must hold a non-resident pharmacy permit from the North Dakota Board of Pharmacy. As of mid-2025, no large 503A compounder is physically headquartered in North Dakota, but several nationally operating 503A pharmacies are permitted to serve ND patients. HealthRX partners with pharmacies that are PCAB-accredited (Pharmacy Compounding Accreditation Board), which provides an additional quality layer beyond minimum state requirements.

Key quality markers to look for in a 503A NMN compounder:

• Certificate of Analysis (COA) from a third-party ISO-17025 accredited lab for each batch.
• Residual solvent testing per USP <467> standards (USP 467 via NIH).
• Microbial limits testing per USP <2021>.
• Labeled potency within 90% to 110% of stated dose.

Patients should request a COA before accepting the first shipment. A pharmacy unwilling to share its COA should not be used.

Cost and Coverage in North Dakota

North Dakota Medicaid does not cover NMN or NR for any indication as of July 2025. Private insurance plans rarely cover compounded NAD+ precursors because they lack FDA-approved drug status. Patients pay entirely out of pocket.

Typical costs through a PCAB-accredited 503A pharmacy:

• NMN 250 mg capsules, 90-day supply: approximately $85 to $130.
• NMN 500 mg capsules, 90-day supply: approximately $130 to $190.
• NR 300 mg capsules, 90-day supply: approximately $75 to $110.
• NR 1 to 000 mg capsules, 90-day supply: approximately $180 to $260.

HealthRX telehealth consultation fees are separate and are not reimbursable through most insurance plans for this indication. HSA and FSA funds may be applicable depending on plan terms; patients should verify with their plan administrator (IRS Publication 502).

Transferring an Existing Prescription to North Dakota

If a patient relocates to North Dakota with an active compounded NMN or NR prescription written by a licensed out-of-state prescriber, the prescription remains valid provided:

1. The prescriber holds or obtains a valid North Dakota prescribing license.
2. The dispensing pharmacy holds a North Dakota non-resident pharmacy permit.
3. The prescription has remaining refills within its 1-year expiration window.

A prescription written by an unlicensed out-of-state prescriber cannot be legally filled by a North Dakota-permitted pharmacy. In that case, a new consultation with a HealthRX prescriber licensed in North Dakota is the fastest resolution. Patients should bring their prior prescription details (dose, compounding specs, frequency) to the new consultation to minimize re-initiation time (FDA prescription drug labeling regulations).

Safety Considerations and Contraindications

NMN and NR are generally well tolerated across published trials. Absolute contraindications have not been formally established in FDA labeling because these are compounded preparations. HealthRX clinicians apply the following cautions based on trial exclusion criteria and pharmacology:

Active malignancy: NAD+ supports DNA repair and may theoretically support cancer cell survival. Several preclinical studies raise this question (Tummala et al., Cell Rep 2014). Patients with active or recently treated malignancy should discuss risks with their oncologist before starting any NAD+ precursor. This is not a blanket contraindication but requires individualized assessment.

Pregnancy and lactation: No human safety data exists. NMN and NR are not recommended during pregnancy or breastfeeding (NCBI reproductive toxicology reference).

High-dose niacin interactions: Combining NMN or NR with prescription niacin (nicotinic acid) at doses above 1 to 000 mg/day may produce additive flushing and hepatotoxic risk. Lipid-lowering niacin prescriptions should be disclosed at the telehealth consult.

Metformin co-administration: Metformin inhibits complex I of the mitochondrial respiratory chain and may blunt NAD+ precursor benefits in skeletal muscle. Patients on metformin for type 2 diabetes may still receive NMN or NR, but expectations for metabolic benefit should be tempered (Kulkarni et al., Nat Aging 2020).